~~<i id='EE17CB30CE'><strike id='EE17CB30CE'><tt id='EE17CB30CE'><pre id='EE17CB30CE'></pre></tt></strike></i>~~

Home» explore» entertainment

entertainment

author：entertainment 2025-09-06 10:15:25 Page View：44

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Abbott's new stent may help patients with peripheral artery disease
Next article： The cancer drug shortage isn’t new — and neither are the solutions

comprehensive

In age of alternative facts, a scholarly course on calling out crap

Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

As H5N1 spreads in cows, experts warn against drinking raw milk

RobertF.Bukaty/APScientistswhoknowaboutthetypesofpathogens—E.coliandSalmonellaamongthem— thatcanbetr

Virginia high school admissions case could be legal follow

3:24DemonstratorsprotestoutsideoftheSupremeCourtinWashington,Thursday,June29,2023,aftertheSupremeCou

A letter from the executive editor: STAT UnitedHealth investigation

MikeReddyforSTATIwanttobringyourattentiontoavitallyimportant investigation STAThaspublishedtoday.For